Running Late: FDA Review Timelines Lengthen For New Product Applications
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result
You may also be interested in...
FDA's Near (And Far) Misses: Applications With Overdue Review Decisions
FDA's Near (And Far) Misses: Applications With Overdue Review Decisions
On Time In Hard Times: FDA's User Fee Goal Performance
On Time In Hard Times: FDA's User Fee Goal Performance
CDER New Drug Reviews Are At 80%-90% Of User Fee Goals, Jenkins Says
The Center for Drug Evaluation and Research's performance in reviewing applications for new drugs and biologics within the timelines specified by the Prescription Drug User Fee Act has slipped to 80 percent to 90 percent